



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/926,431	03/06/2002	Siba K. Samal	108172-00070	2502
4372	7590 11/08/2004		EXAM	INER
ARENT FOX KINTNER PLOTKIN & KAHN		SCHEINER, LAURIE A		
1050 CONNE SUITE 400	CTICUT AVENUE, N.	W.	, ART UNIT	PAPER NUMBER
	ON, DC 20036		1648	

DATE MAILED: 11/08/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.	
				EXAMINER	
			ART UNIT	PAPER]

11032004

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR §§ 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN A **ONE MONTH** EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR §§ 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR §1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio

(<<hr/>http://www.uspto.gov/ebc/efs/downloads/documents.htm>>, EFS Submission User Manual - ePAVE)

2. Mailed to:

Mail Stop Sequence Commissioner for Patents P.O. Box 22313-1450 Alexandria, VA 22313-1450 3. Mailed by Federal Express, United Parcel Service or other delivery service to:

U. S. Patent and Trademark Office

Box Sequence, Room 1B03-Mailroom

Crystal Plaza Two 220 20th Street S.

Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at:

U. S. Patent and Trademark Office Box Sequence, Customer Window, Lobby, Room 1B03 Crystal Plaza Two 220 20th Street S. Arlington, Virginia 22202

Any inquiry concerning this communication should be directed to the examiner, Laurie Scheiner, Technology Center 1600, Group 1640, Art Unit 1648, whose telephone number is (571) 272-0910. The examiner can normally be reached on weekdays from 9 a.m. to 5 p.m. If unable to reach the examiner, James Housel, SPE, can be contacted at (571) 272-0902.

Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice To Comply.

Any inquiry of a general nature or relating to the status of this application, or requests to supply missing elements from Office communications, should be directed to the Group receptionist whose telephone number is (571) 272-1600.

LAURIE SCHEINER
PRIMARY EXAMINER

NOTICE TO COMPLY

Application/Control No.	Applicant(s)	
09/926,431	SAMAL ET AL.	
Examiner	Art Unit	
Laurie A. Scheiner	1648	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- submitted as required by 37 C.F.R. 1.825(d).

 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as

unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be

5. The computer readable form that has been filed with this application has been found to be damaged and/or

☐ 7. Other: .

Applicant Must Provide:

required by 37 C.F.R. 1.821(e).

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

U.S. Patent and Trademark Office

Part of Paper No. 11032004

Sequence Count Sheet		Application/Control No.	Applicant(s)	
		09/926,431	SAMAL ET AL.	
		Examiner	Art Unit	
		Laurie A. Scheiner	1648	
		Eddie / L Gorielle/	10-10	
			DATE OF COUNT	
Marile and				
Mark only	one space below			
	(CRFN) (CRF is unreadable; use 0	CRF Diskette Problem Repo	ort)	
<u> </u>	, , ,		··· ·	
		•		
	(CRFD) (CRF does not comply; us	se Notice to Comply)		
	(50 Mailes to 30 mp.y/		
			8	
\boxtimes	(CRFR) (CRF required but none s	submitted: use Notice to Cor	noly)	
K	(a mary (a mary a mar			
			·	
	(bona fide) (second or subseque	ent letter to applicant reportir	ng bona fide attempt to	
	comply; use Notice to Comply and		ig some neo attompt to	
		,		
	(non bona fide) (second or subs			
	attempt to comply; use Notice to Co	omply and send copy of RSI	-)	
			·	
		•		
			-	
		•		
			ļ	